{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:48:31Z","timestamp":1791215311849,"version":"4.1.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T00:00:00Z","timestamp":1396051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00277-014-2058-4","type":"journal-article","created":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T08:43:46Z","timestamp":1395996226000},"page":"913-921","source":"Crossref","is-referenced-by-count":29,"title":["Therapy of HIV-associated lymphoma\u2014recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGN\u00c4), in cooperation with the German AIDS Society (DAIG)"],"prefix":"10.1007","volume":"93","author":[{"given":"Marcus","family":"Hentrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Mosthaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Siehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Hensel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,29]]},"reference":[{"key":"2058_CR1","first-page":"590","volume":"48","author":"C Lewden","year":"2008","unstructured":"Lewden C, May T, Rosenthal E, Burty C, Bonnet F et al (2008) Changes in causes of death among adults infected by HIV between 2000 and 2005: the \u201cMortalit\u00e9 2000 and 2005\u201d surveys (ANRS EN19 and Mortavic). J AIDS 48:590\u2013598","journal-title":"J AIDS"},{"key":"2058_CR2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/319366","volume":"32","author":"MA Kish","year":"2001","unstructured":"Kish MA (2001) Guide to development of practice guidelines. Clin Infect Dis 32:851\u2013854","journal-title":"Clin Infect Dis"},{"key":"2058_CR3","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1002\/cncr.25530","volume":"116","author":"EC Seaberg","year":"2010","unstructured":"Seaberg EC, Wiley D, Mart\u00ednez-Maza O, Chmiel JS, Kingesley L et al (2010) Cancer incidence in the Multicenter AIDS Cohort Study before and during the HAART era: 1984\u20132007. Cancer 116:5507\u20135516","journal-title":"Cancer"},{"key":"2058_CR4","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/01.aids.0000238411.75324.59","volume":"20","author":"EA Engels","year":"2006","unstructured":"Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS et al (2006) Trends in cancer risk among people with AIDS in the United States 1980\u20132002. AIDS 20:1645\u20131654","journal-title":"AIDS"},{"key":"2058_CR5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3324\/haematol.2008.002691","volume":"94","author":"M Bower","year":"2009","unstructured":"Bower M, Fisher M, Hill T, Reeves I, Walsh J et al (2009) CD4 counts and the risk of systemic non-Hodgkin\u2019s lymphoma in individuals with HIV in the UK. Haematologica 94:875\u2013880","journal-title":"Haematologica"},{"key":"2058_CR6","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S1470-2045(09)70282-7","volume":"10","author":"M Guiguet","year":"2009","unstructured":"Guiguet M, Bou\u00e9 F, Cadranel J, Lang JM, Rosenthal E et al (2009) Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 10:1152\u20132259","journal-title":"Lancet Oncol"},{"key":"2058_CR7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2009.25.1322","volume":"28","author":"O Landgren","year":"2010","unstructured":"Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K et al (2010) Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 28:773\u2013779","journal-title":"J Clin Oncol"},{"key":"2058_CR8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ajh.23236","volume":"87","author":"M Bibas","year":"2012","unstructured":"Bibas M, Trotta MP, Cozzi-Lepri A, Lorenzini P, Pinnetti C et al (2012) Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am J Hematol 87:749\u2013753","journal-title":"Am J Hematol"},{"key":"2058_CR9","first-page":"340","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"M Raphael","year":"2008","unstructured":"Raphael M, Said J, Borisch B, Cesarman E, Harris NL et al (2008) Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon, pp 340\u2013342","edition":"4"},{"key":"2058_CR10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1634\/theoncologist.12-5-569","volume":"12","author":"YB Chen","year":"2007","unstructured":"Chen YB, Rahemtullah A, Hochberg E (2007) Primary effusion lymphoma. Oncologist 12:569\u2013576","journal-title":"Oncologist"},{"key":"2058_CR11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1473-3099(08)70067-7","volume":"8","author":"DJ Riedel","year":"2008","unstructured":"Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, Redfield RR, Gilliam BL (2008) Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis 8:261\u2013267","journal-title":"Lancet Infect Dis"},{"issue":"Suppl7","key":"2058_CR12","doi-asserted-by":"crossref","first-page":"vii78","DOI":"10.1093\/annonc\/mds273","volume":"23","author":"H Tilly","year":"2012","unstructured":"Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O et al (2012) Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl7):vii78\u201382","journal-title":"Ann Oncol"},{"key":"2058_CR13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2004-11-4278","volume":"107","author":"WH Navarro","year":"2006","unstructured":"Navarro WH, Kaplan LD (2006) AIDS-related lymphoproliferative disease. Blood 107:13\u201320","journal-title":"Blood"},{"key":"2058_CR14","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/00002030-200307040-00013","volume":"17","author":"C Hoffmann","year":"2003","unstructured":"Hoffmann C, Wolf E, F\u00e4tkenheuer G, Buhk T, Stoehr A et al (2003) Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 17:1521\u20131529","journal-title":"AIDS"},{"key":"2058_CR15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.7326\/0003-4819-143-4-200508160-00007","volume":"143","author":"M Bower","year":"2005","unstructured":"Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C et al (2005) A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 143:265\u2013273","journal-title":"Ann Intern Med"},{"key":"2058_CR16","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/cncr.21759","volume":"106","author":"R Weiss","year":"2006","unstructured":"Weiss R, Mitrou P, Arast\u00e9h K, Schuermann D, Hentrich M et al (2006) Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival\u2014results of the German Multicenter Trial. Cancer 106:1560\u20131568","journal-title":"Cancer"},{"key":"2058_CR17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/QAD.0b013e32835e069d","volume":"27","author":"P Schommers","year":"2013","unstructured":"Schommers P, Wyen C, Hentrich M, Gillor D, Zoufaly A (2013) Poor outcome of HIV-infected patients with plasmablastic lymphoma (PBL)\u2014results from the German AIDS related lymphoma (ARL) cohort study. AIDS 27:842\u2013845","journal-title":"AIDS"},{"key":"2058_CR18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1468-1293.2008.00608.x","volume":"9","author":"M Bower","year":"2008","unstructured":"Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S et al (2008) British HIV association guidelines for HIV-associated malignancies 2008. HIV Med 9:336\u2013388","journal-title":"HIV Med"},{"key":"2058_CR19","unstructured":"European AIDS Clinical Society guidelines Version 7 October 2013 (2013). Part II: ART in HIV-positive persons. http:\/\/www.eacsociety.org\/Portals\/0\/Guidelines_Online_131014.pdf"},{"key":"2058_CR20","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1097\/QAD.0b013e32833db989","volume":"24","author":"A Cingolani","year":"2010","unstructured":"Cingolani A, Torti L, Pinnetti C, de Gaetano DK, Murri R et al (2010) Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. AIDS 24:2408\u20132412","journal-title":"AIDS"},{"key":"2058_CR21","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.3109\/10428194.2012.697560","volume":"53","author":"HM Ezzat","year":"2012","unstructured":"Ezzat HM, Cheung MC, Hicks LK, Boro J, Montaner JS et al (2012) Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Leuk Lymphoma 53:2390\u20132396","journal-title":"Leuk Lymphoma"},{"key":"2058_CR22","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2007-10-115659","volume":"111","author":"M Bower","year":"2008","unstructured":"Bower M, Stebbing J, Tuthill M, Campbell V, Krell J et al (2008) Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. Blood 111:3986\u20133990","journal-title":"Blood"},{"key":"2058_CR23","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2012.41.8137","volume":"30","author":"M Hentrich","year":"2012","unstructured":"Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK et al (2012) Stage-adapted treatment of human immunodeficiency virus associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol 30:4117\u20134123","journal-title":"J Clin Oncol"},{"key":"2058_CR24","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","volume":"101","author":"RF Little","year":"2003","unstructured":"Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF et al (2003) Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 101:4653\u20134659","journal-title":"Blood"},{"key":"2058_CR25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00277-013-1698-0","volume":"92","author":"S Neumann","year":"2013","unstructured":"Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilientfeld-Total M (2013) Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 92:433\u2013442","journal-title":"Ann Hematol"},{"key":"2058_CR26","unstructured":"European AIDS Clinical Society guidelines Version 7 October 2013 (2013). Part V: Opportunistic infections. http:\/\/www.eacsociety.org\/Portals\/0\/Guidelines_Online_131014.pdf"},{"key":"2058_CR27","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","volume":"28","author":"AS Artz","year":"2010","unstructured":"Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS et al (2010) American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28:3199\u20133202","journal-title":"J Clin Oncol"},{"key":"2058_CR28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2012.12.004","volume":"87","author":"M Mandal\u00e0","year":"2013","unstructured":"Mandal\u00e0 M, Fagiuoli S, Francisci D, Bruno R, Merelli B et al (2013) Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. Crit Rev Oncol Hematol 87:12\u201327","journal-title":"Crit Rev Oncol Hematol"},{"key":"2058_CR29","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdj132","volume":"17","author":"M Sandherr","year":"2006","unstructured":"Sandherr M, Einsele H, Hebart H, Kahl C, Kern W et al (2006) Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 17:1051\u20131059","journal-title":"Ann Oncol"},{"key":"2058_CR30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.11665","volume":"94","author":"OA Cornely","year":"2009","unstructured":"Cornely OA, B\u00f6hme A, Buchheidt D, Einsele H, Heinz WJ et al (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94:113\u2013112","journal-title":"Haematologica"},{"key":"2058_CR31","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","volume":"106","author":"LD Kaplan","year":"2005","unstructured":"Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E et al (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106:1538\u20131543","journal-title":"Blood"},{"key":"2058_CR32","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","volume":"24","author":"F Bou\u00e9","year":"2006","unstructured":"Bou\u00e9 F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A et al (2006) Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin\u2019s lymphoma. J Clin Oncol 24:4123\u20134128","journal-title":"J Clin Oncol"},{"key":"2058_CR33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2007.06943.x","volume":"140","author":"JM Ribera","year":"2008","unstructured":"Ribera JM, Oriol A, Morgades M, Gonz\u00e1lez-Barca E, Miralles P et al (2008) Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 140:411\u2013419","journal-title":"Br J Haematol"},{"key":"2058_CR34","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2001.19.8.2171","volume":"19","author":"L Ratner","year":"2001","unstructured":"Ratner L, Lee J, Tang S, Redden D, Hamzeh F et al (2001) Chemotherapy for human immunodeficiency virus-associated non-Hodgkin\u2019s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19:2171\u20132178","journal-title":"J Clin Oncol"},{"key":"2058_CR35","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","volume":"105","author":"M Spina","year":"2005","unstructured":"Spina M, J\u00e4ger U, Sparano JA, Talamini R, Simonelli C et al (2005) Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 105:1891\u20131897","journal-title":"Blood"},{"key":"2058_CR36","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","volume":"115","author":"K Dunleavy","year":"2010","unstructured":"Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS et al (2010) The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 115:3017\u20133024","journal-title":"Blood"},{"key":"2058_CR37","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","volume":"115","author":"JA Sparano","year":"2010","unstructured":"Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC et al (2010) Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 115:3008\u20133016","journal-title":"Blood"},{"key":"2058_CR38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/QAD.0b013e32834f30fa","volume":"26","author":"C Wyen","year":"2012","unstructured":"Wyen C, Jensen B, Hentrich M, Siehl J, Sabranski M et al (2012) Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. AIDS 26:457\u2013464","journal-title":"AIDS"},{"key":"2058_CR39","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","volume":"122","author":"S Barta","year":"2013","unstructured":"Barta S, Xue X, Wang D, Tamari R, Lee JY et al (2013) Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood 122:3251\u20133262","journal-title":"Blood"},{"key":"2058_CR40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1200\/JCO.2012.42.4648","volume":"31","author":"AM Levine","year":"2013","unstructured":"Levine AM, Noy A, Lee JY, Tam W, Ramos JC et al (2013) Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol 31:58\u201364","journal-title":"J Clin Oncol"},{"key":"2058_CR41","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2004.08.195","volume":"22","author":"JA Sparano","year":"2004","unstructured":"Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A et al (2004) Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin\u2019s lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 22:1491\u20131500","journal-title":"J Clin Oncol"},{"key":"2058_CR42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379\u2013391","journal-title":"Lancet Oncol"},{"key":"2058_CR43","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1200\/JCO.2008.20.5450","volume":"27","author":"A Chadburn","year":"2009","unstructured":"Chadburn A, Chiu A, Lee JY, Chen X, Hyjek E et al (2009) Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol 27:5039\u20135048","journal-title":"J Clin Oncol"},{"key":"2058_CR44","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/cncr.24922","volume":"116","author":"M Spina","year":"2010","unstructured":"Spina M, Chimienti E, Martellotta F, Vaccher E, Berretta M et al (2010) Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 116:1495\u20131501","journal-title":"Cancer"},{"key":"2058_CR45","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","volume":"119","author":"D Dunleavy","year":"2012","unstructured":"Dunleavy D, Wilson WH (2012) How I treat HIV-associated lymphoma. Blood 119:3245\u20133255","journal-title":"Blood"},{"key":"2058_CR46","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","volume":"113","author":"V Boehme","year":"2009","unstructured":"Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M (2009) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113:3896\u20133902","journal-title":"Blood"},{"key":"2058_CR47","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/annonc\/mdr440","volume":"23","author":"N Schmitz","year":"2012","unstructured":"Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E et al (2012) CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 23:1267\u20131273","journal-title":"Ann Oncol"},{"key":"2058_CR48","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S1470-2045(11)70140-1","volume":"12","author":"R Kridel","year":"2011","unstructured":"Kridel R, Dietrich PY (2011) Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncology 12:1258\u20131266","journal-title":"Lancet Oncology"},{"issue":"ASH Annual meet","key":"2058_CR49","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1182\/blood.V112.11.3596.3596","volume":"112","author":"K Herbert","year":"2008","unstructured":"Herbert K, Wolff M, Carney D, Westerman DA, Januszewicz H et al (2008) The addition of systemic high-dose methotrexate (HD-MTX) to intrathecal chemotherapy (IT) for central nervous system (CNS) prophylaxis substantilly reduces CNS recurrence rates in patients with at-risk aggressive lymphoma: a historically controlled prospective study. Blood 112(ASH Annual meeting abstracts):3596","journal-title":"Blood"},{"key":"2058_CR50","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1002\/cncr.25278","volume":"116","author":"JS Abramson","year":"2010","unstructured":"Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C et al (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 116:4283\u20134290","journal-title":"Cancer"},{"key":"2058_CR51","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2005-08-3119","volume":"107","author":"D Mazhar","year":"2006","unstructured":"Mazhar D, Stebbbing J, Lewis R, Nelson M, Gazzard BG, Bower M (2006) The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe. Blood 107:3412\u20133414","journal-title":"Blood"},{"key":"2058_CR52","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1080\/10428190600685467","volume":"47","author":"C Hoffmann","year":"2006","unstructured":"Hoffmann C, Wolf E, Wyen C, F\u00e4tkenheuer G, Van Lunzen J et al (2006) AIDS-associated Burkitt- or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma 47:1872\u20131880","journal-title":"Leuk Lymphoma"},{"key":"2058_CR53","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.27918","volume":"119","author":"J-M Ribera","year":"2013","unstructured":"Ribera J-M, Garc\u0131a O, Grande C, Esteve J, Oriol A et al (2013) Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer 119:1660\u20131668","journal-title":"Cancer"},{"key":"2058_CR54","doi-asserted-by":"crossref","unstructured":"Xicoy B, Ribera J-M, M\u00fcller M, Garc\u00eda O, Hoffmann C et al. (2014) Dose-intense chemotherapy including rituximab is highly effective but toxic in HIV-infected patients with Burkitt's lymphoma\/eukemia: parallel study of 81 patients. Leuk Lymphoma Feb 25 [Epub ahead of print]","DOI":"10.3109\/10428194.2013.878933"},{"key":"2058_CR55","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/cncr.10365","volume":"94","author":"J Cortes","year":"2002","unstructured":"Cortes J, Thomas D, Rios A, Koller C, O\u2019Brien S et al (2002) Hyperfractionated cylclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma\/leukemia. Cancer 94:1492\u20131499","journal-title":"Cancer"},{"key":"2058_CR56","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/cncr.11628","volume":"98","author":"ES Wang","year":"2003","unstructured":"Wang ES, Strauss DJ, Teruya-Feldstein J, Qin J, Portlock C et al (2003) Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate\/ifosfamide, etoposide, and high dose cytarabine (CODOX-M\/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 98:1196\u20131205","journal-title":"Cancer"},{"key":"2058_CR57","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood-2006-10-051771","volume":"110","author":"L Galicier","year":"2007","unstructured":"Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT et al (2007) Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma\/leukemia: a prospective study. Blood 110:2846\u20132854","journal-title":"Blood"},{"key":"2058_CR58","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/QAD.0b013e3283301578","volume":"24","author":"S Montoto","year":"2010","unstructured":"Montoto S, Wilson J, Shaw K, Heath M, Wilson A et al (2010) Excellent immunological recovery following CODOXM\/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt\u2019s lymphoma. AIDS 24:851\u2013856","journal-title":"AIDS"},{"key":"2058_CR59","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","volume":"369","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D et al (2013) Low-intensity therapy in adults with Burkitt's lymphoma. New Engl J Med 369:1915\u20131925","journal-title":"New Engl J Med"},{"key":"2058_CR60","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","volume":"118","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Furman M, Beltr\u00e1n BE, Bibas M, Bower M et al (2012) Human immunodeficiency virus-associated plasmablastic lymphoma. Poor prognosis in the era of highly active antiretroviral therapy. Cancer 118:5270\u20135277","journal-title":"Cancer"},{"issue":"suppl abstr","key":"2058_CR61","doi-asserted-by":"crossref","first-page":"e19562","DOI":"10.1200\/jco.2009.27.15_suppl.e19562","volume":"27","author":"P Bose","year":"2009","unstructured":"Bose P, Thompson CL, Gandhi DG, Ghabach BS, Ozer H (2009) Response of AIDS related plasmablastic lymphoma (PBL) to bortezomib. J Clin Oncol 27(suppl abstr):e19562","journal-title":"J Clin Oncol"},{"key":"2058_CR62","first-page":"287","volume":"36","author":"NS Saba","year":"2013","unstructured":"Saba NS, Dang D, Saba J, Cao C, Janbain M et al (2013) Bortezomib in plasmablastic lymphoma: a case report and review of the literature. Onkologie 36:287\u2013291","journal-title":"Onkologie"},{"key":"2058_CR63","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2003.06.013","volume":"21","author":"C Simonelli","year":"2003","unstructured":"Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R et al (2003) Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 21:3948\u20133954","journal-title":"J Clin Oncol"},{"key":"2058_CR64","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1200\/JCO.2005.07.084","volume":"23","author":"E Boulanger","year":"2005","unstructured":"Boulanger E, G\u00e9rard L, Gabarre J, Molina JM, Rapp C et al (2005) Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 23:4372\u20134380","journal-title":"J Clin Oncol"},{"key":"2058_CR65","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood.V99.7.2331","volume":"99","author":"E Oksenhendler","year":"2002","unstructured":"Oksenhendler E, Boulanger E, Galicier L, Du MQ, Dupin N et al (2002) High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99:2331\u20132336","journal-title":"Blood"},{"key":"2058_CR66","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/0003-4819-147-12-200712180-00003","volume":"147","author":"M Bower","year":"2007","unstructured":"Bower M, Powles T, Williams S, Davis TN, Atkins M et al (2007) Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 147:836\u2013839","journal-title":"Ann Intern Med"},{"key":"2058_CR67","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2010-07-290213","volume":"116","author":"M Bower","year":"2010","unstructured":"Bower M (2010) How I treat HIV-associated multicentric Castleman disease. Blood 116:4415\u20134421","journal-title":"Blood"},{"key":"2058_CR68","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2007.10.6732","volume":"25","author":"L G\u00e9rard","year":"2007","unstructured":"G\u00e9rard L, B\u00e9rezn\u00e9 A, Galicier L, Meignin V, Obadia M et al (2007) Prospective study of rituximab in chemotherapy- dependent human immunodeficiency virus associated multicentric Castleman\u2019s disease: ANRS 117 Castleman Trial. J Clin Oncol 25:3350\u20133356","journal-title":"J Clin Oncol."},{"key":"2058_CR69","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1182\/blood-2011-02-333633","volume":"118","author":"C Hoffmann","year":"2011","unstructured":"Hoffmann C, Schmid H, M\u00fcller M, Teutsch C, van Lunzen J et al (2011) Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 118:3499\u20133503","journal-title":"Blood"},{"key":"2058_CR70","first-page":"1100","volume":"89","author":"J Gabarre","year":"2004","unstructured":"Gabarre J, Marcelin A-G, Azar N, Choquet S, L\u00e9vy V et al (2004) High-dose therapy plus autologous hematopietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV-disease. Haematologica 89:1100\u20131108","journal-title":"Haematologica"},{"key":"2058_CR71","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1182\/blood-2009-02-202762","volume":"114","author":"A Re","year":"2009","unstructured":"Re A, Michieli M, Casari S, Allione B, Cattaneo C et al (2009) High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 114:1306\u20131313","journal-title":"Blood"},{"key":"2058_CR72","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2008.18.2683","volume":"27","author":"P Balsalobre","year":"2009","unstructured":"Balsalobre P, Diez-Martin JL, Re A, Michieli M, Ribera JM et al (2009) Autologous stem cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 27:2192\u20132198","journal-title":"J Clin Oncol"},{"key":"2058_CR73","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2013.089052","volume":"98","author":"A Re","year":"2013","unstructured":"Re A, Cattaneo C, Skert C, Balsalobre P, Michieli M et al (2013) Stem cell mobilization in HIV seropositive patients with lymphoma. Haematologica 98:1762\u20131768","journal-title":"Haematologica"},{"key":"2058_CR74","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1182\/blood-2008-12-195388","volume":"113","author":"JL Diez-Martin","year":"2009","unstructured":"Diez-Martin JL, Balsalobre P, Re A, Michieli M, Ribera JM et al (2009) Comparable survival between HIV+and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 113:6011\u20136014","journal-title":"Blood"},{"key":"2058_CR75","first-page":"117","volume":"108","author":"M Hensel","year":"2011","unstructured":"Hensel M, Goetzenich A, Lutz T, Stoehr A, Moll A et al (2011) HIV and cancer in Germany. Dtsch Arztebl Int 108:117\u2013122","journal-title":"Dtsch Arztebl Int"},{"key":"2058_CR76","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jnci\/djj302","volume":"98","author":"M Bower","year":"2006","unstructured":"Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Stebbing J (2006) Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst 98:1088\u20131091","journal-title":"J Natl Cancer Inst"},{"key":"2058_CR77","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1097\/00002030-200111090-00007","volume":"15","author":"C Hoffmann","year":"2001","unstructured":"Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A et al (2001) Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 15:2119\u20132127","journal-title":"AIDS"},{"key":"2058_CR78","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.hoc.2005.05.004","volume":"19","author":"YL Kasamon","year":"2005","unstructured":"Kasamon YL, Ambinder RF (2005) AIDS-related primary central nervous system lymphoma. Hematol Oncol Clin North Am 19:665\u2013687","journal-title":"Hematol Oncol Clin North Am"},{"key":"2058_CR79","doi-asserted-by":"crossref","unstructured":"Uldrick TS, Pipkin S, Scheer S, Hesssol NA. (2013) Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma. AIDS Sep 26 [Epub ahead of print]","DOI":"10.1097\/QAD.0000000000000030"},{"key":"2058_CR80","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/cncr.20300","volume":"100","author":"ME Newell","year":"2004","unstructured":"Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE et al (2004) Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer 100:2627\u20132636","journal-title":"Cancer"},{"key":"2058_CR81","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1600-0609.2010.01424.x","volume":"84","author":"H Nagai","year":"2010","unstructured":"Nagai H, Odawara T, Ajisawa A, Tanuma J, Hagiwara S et al (2010) Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol 84:499\u2013505","journal-title":"Eur J Haematol"},{"key":"2058_CR82","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1089\/apc.2007.0009","volume":"21","author":"DM Aboulafia","year":"2007","unstructured":"Aboulafia DM, Puswella AL (2007) Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment. AIDS Patient Care STDS 21:900\u2013097","journal-title":"AIDS Patient Care STDS"},{"key":"2058_CR83","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1200\/JCO.2011.39.9642","volume":"30","author":"G Travi","year":"2012","unstructured":"Travi G, Ferreri AJ, Cinque P, Gerevini S, Ponzoni M (2012) Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone. J Clin Oncol 30:e119\u2013121","journal-title":"J Clin Oncol"},{"key":"2058_CR84","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/00002030-199714000-00009","volume":"11","author":"C Jacomet","year":"1997","unstructured":"Jacomet C, Girard PM, Librette MG, Farese VL, Monfort L, Rozenbaum W (1997) Intravenous methotrexate for primary central nervous system non-Hodgkin\u2019s lymphoma in AIDS. AIDS 11:1725\u20131730","journal-title":"AIDS"},{"key":"2058_CR85","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2003.01.096","volume":"21","author":"M Herida","year":"2003","unstructured":"Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I et al (2003) Incidence of non-AIDS-defining cancer before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21:3447\u20133453","journal-title":"J Clin Oncol"},{"key":"2058_CR86","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2008.19.6626","volume":"27","author":"T Powles","year":"2009","unstructured":"Powles T, Robinson D, Stebbing J, Shamash J, Nelson M et al (2009) Highly active antiretroviral therapy and the incidence of non\u2013AIDS-defining cancers in people with HIV infection. J Clin Oncol 27:884\u2013890","journal-title":"J Clin Oncol"},{"key":"2058_CR87","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.bjc.6605756","volume":"103","author":"S Franceschi","year":"2010","unstructured":"Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F et al (2010) Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 103:416\u2013422","journal-title":"Br J Cancer"},{"key":"2058_CR88","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood-2006-05-024109","volume":"108","author":"RJ Biggar","year":"2006","unstructured":"Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA (2006) Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS. Blood 108:3786\u20133791","journal-title":"Blood"},{"key":"2058_CR89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2011-02-339275","volume":"118","author":"E Lanoy","year":"2011","unstructured":"Lanoy E, Rosenberg PS, Fily F, Lascaux AS, Martinez V et al (2011) HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood 118:44\u201349","journal-title":"Blood"},{"key":"2058_CR90","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1182\/blood-2010-08-301531","volume":"117","author":"J Bohlius","year":"2011","unstructured":"Bohlius J, Schmidlin K, Bou\u00e9 F, F\u00e4tkenheuer G, May M et al (2011) HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood 117:6100\u20136108","journal-title":"Blood"},{"key":"2058_CR91","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002030-200301030-00011","volume":"17","author":"L G\u00e9rard","year":"2003","unstructured":"G\u00e9rard L, Galicier L, Boulanger E, Quint L, Lebrette MG et al (2003) Improved survival in HIV-related Hodgkin\u2019s lymphoma since the introduction of highly active antiretroviral therapy. AIDS 17:81\u201387","journal-title":"AIDS"},{"key":"2058_CR92","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2004.04934.x","volume":"124","author":"C Hoffmann","year":"2004","unstructured":"Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ et al (2004) Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin\u2019s disease. Br J Haematol 124:455\u2013462","journal-title":"Br J Haematol"},{"key":"2058_CR93","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/annonc\/mdl063","volume":"17","author":"M Hentrich","year":"2006","unstructured":"Hentrich M, Maretta L, Chow KU, Bogner JR, Sch\u00fcrmann D et al (2006) Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin\u2019s disease: results of a multicenter study. Ann Oncol 17:914\u2013919","journal-title":"Ann Oncol"},{"key":"2058_CR94","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3324\/haematol.10479","volume":"92","author":"B Xicoy","year":"2007","unstructured":"Xicoy B, Ribera J-M, Miralles P, Berenguer J, Rubio R et al (2007) Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin\u2019s lymphoma. Haematologica 92:191\u2013198","journal-title":"Haematologica"},{"key":"2058_CR95","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2011.41.4193","volume":"30","author":"S Montoto","year":"2012","unstructured":"Montoto S, Shaw K, Okosun J, Gandhi S, Fields P et al (2012) HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol 30:4111\u20134116","journal-title":"J Clin Oncol"},{"key":"2058_CR96","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1182\/blood-2002-03-0989","volume":"100","author":"M Spina","year":"2002","unstructured":"Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C et al (2002) Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 100:1984\u20131988","journal-title":"Blood"},{"key":"2058_CR97","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert A, Pl\u00fctschow A, Eich HT, Lohri A, D\u00f6rken B et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640\u2013652","journal-title":"N Engl J Med"},{"key":"2058_CR98","first-page":"177","volume":"110","author":"M Rancea","year":"2013","unstructured":"Rancea M, Engert A, von Tresckow B, Halbsguth T, Behringer K, Skoetz N (2013) Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up. Dtsch Arztebl Int 110:177\u201383","journal-title":"Dtsch Arztebl Int"}],"updated-by":[{"DOI":"10.1007\/s00277-014-2098-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2058-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2058-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2058-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T05:00:27Z","timestamp":1648702827000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2058-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,29]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["2058"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2058-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00277-014-2098-9","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,29]]}}}